Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A2B Trial: Alpha 2 Agonists for Sedation in Critical Illness
NCT03653832Phase 3Completed
- Sponsor
- University of Edinburgh
- Start
- Dec 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexmedetomidine and clonidine in critical illness (3 arms), sponsored by University of Edinburgh. Primary endpoint: Time to First Successful Extubation Post-randomisation up to 180 days. Started Dec 2018; status: completed.
02
Drugs
dexmedetomidineclonidine
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT03653832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653832.